Brucella antigens (BhuA, 7α-HSDH, FliC) in poly I:C adjuvant as potential vaccine candidates against brucellosis
- PMID: 34673003
- DOI: 10.1016/j.jim.2021.113172
Brucella antigens (BhuA, 7α-HSDH, FliC) in poly I:C adjuvant as potential vaccine candidates against brucellosis
Abstract
A promising strategy for controlling animal brucellosis is vaccination with commercial vaccine strains (Brucella melitensis Rev.1 and Brucella abortus RB51). Owing to safety concerns associated with these vaccines, developing a more effective and safe vaccine is essential. In this study, we examined the capacity of BhuA, 7α-HSDH or FliC antigens in the presence or absence of adjuvant in eliciting immune responses against brucellosis. After cloning, expression and purification, these proteins were used to examine immunologic responses. All immunized mice induced a vigorous IgG, with a predominant IgG2a response. Moreover, splenocytes of immunized mice proliferated and produced IL-2 and IFN-γ, suggesting the induction of cellular immunity. The high IgG2a/IgG1 ratio and IL-2 and IFN-γ indicated a Th1-oriented immune response in test groups. BhuA-, 7α-HSDH- or FliC- poly I:C formulations were the most effective at inducing Th1 immune response compared to groups immunized with naked proteins. Immunization with proteins protected mice against B. melitensis 16M and B. abortus 544. The proteins in adjuvant induced higher levels of protection than proteins only and exhibited similar degree of protection to live attenuated vaccines. Our results, for first time, introduced five potential candidates for subunit vaccine development against B. melitensis and B. abortus infection.
Keywords: 7α-HSDH; BhuA; Brucella; FliC; Poly I:C; Vaccine candidate.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Nanoparticle-Based Vaccines for Brucellosis: Calcium Phosphate Nanoparticles-Adsorbed Antigens Induce Cross Protective Response in Mice.Int J Nanomedicine. 2020 May 29;15:3877-3886. doi: 10.2147/IJN.S249942. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32581535 Free PMC article.
-
Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection.Int Immunopharmacol. 2019 Oct;75:105829. doi: 10.1016/j.intimp.2019.105829. Epub 2019 Aug 19. Int Immunopharmacol. 2019. PMID: 31437796
-
A combined subunit vaccine comprising BP26, Omp25 and L7/L12 against brucellosis.Pathog Dis. 2019 Nov 1;77(8):ftaa002. doi: 10.1093/femspd/ftaa002. Pathog Dis. 2019. PMID: 31971564
-
Brucellosis vaccines based on the open reading frames from genomic island 3 of Brucella abortus.Vaccine. 2018 May 17;36(21):2928-2936. doi: 10.1016/j.vaccine.2018.04.014. Vaccine. 2018. PMID: 29685597 Review.
-
Immune response triggered by Brucella abortus following infection or vaccination.Vaccine. 2015 Jul 17;33(31):3659-66. doi: 10.1016/j.vaccine.2015.05.057. Epub 2015 Jun 3. Vaccine. 2015. PMID: 26048781 Review.
Cited by
-
A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against Brucella melitensis.Clin Exp Vaccine Res. 2025 Jan;14(1):67-76. doi: 10.7774/cevr.2025.14.e3. Epub 2025 Jan 13. Clin Exp Vaccine Res. 2025. PMID: 39927221 Free PMC article.
-
Brucella and Its Hidden Flagellar System.Microorganisms. 2021 Dec 31;10(1):83. doi: 10.3390/microorganisms10010083. Microorganisms. 2021. PMID: 35056531 Free PMC article. Review.
-
Design of a multi-epitope vaccine candidate against Brucella melitensis.Sci Rep. 2022 Jun 16;12(1):10146. doi: 10.1038/s41598-022-14427-z. Sci Rep. 2022. PMID: 35710873 Free PMC article.
-
Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study.AMB Express. 2024 Jan 3;14(1):2. doi: 10.1186/s13568-023-01638-4. AMB Express. 2024. PMID: 38170414 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources